Lupin has informed that it has enclosed a Press Release as regards receipt of USFDA approval for the Company's Sevelamer Carbonate Tablets, 800 mg, to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.
The above information is a part of company’s filings submitted to BSE.